Your browser doesn't support javascript.
loading
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
Richardson, Paul G; Harrison, Simon J; Bringhen, Sara; Schjesvold, Fredrik; Yong, Kwee; Campana, Frank; Le-Guennec, Solenn; Macé, Sandrine; Dimopoulos, Meletios A.
Afiliación
  • Richardson PG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Harrison SJ; Peter MacCallum Cancer Centre & Royal Melbourne Hospital Melbourne, Sir Peter MacCallum Department of Oncology, University of Melbourne Parkville, Victoria, 3010, Australia.
  • Bringhen S; Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino 10126, Italy.
  • Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, Oslo 0188, Norway.
  • Yong K; KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo 0315, Norway.
  • Campana F; Department of Haematology, University College London Hospitals, London WC1N 3BG, UK.
  • Le-Guennec S; Sanofi R&D, Cambridge, MA 02142, USA.
  • Macé S; Currently, Takeda Pharmaceuticals, Cambridge, MA 02142, USA.
  • Dimopoulos MA; Sanofi R&D, Vitry-sur-Seine 94400, France.
Future Oncol ; 17(34): 4797-4812, 2021 Dec.
Article en En | MEDLINE | ID: mdl-34521277
Lay abstract Currently, the majority of patients with multiple myeloma are not cured, and current treatments may not be helpful for patients with poor prognoses, including those with high-risk chromosomal changes, those who have impaired kidney function, those who are elderly and those who are refractory to prior treatments. In this review, we will discuss the benefits of the combination of isatuximab plus pomalidomide and dexamethasone in these difficult-to-treat patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados / Mieloma Múltiple / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Future Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados / Mieloma Múltiple / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Future Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido